Literature DB >> 21294249

Variation in NGFB is associated with primary affective disorders in women.

Donghong Cui1, Huiping Zhang, Bao-Zhu Yang, Jennifer B Listman, Dawei Li, Lawrence H Price, Linda L Carpenter, Audrey R Tyrka, Raymond F Anton, Henry R Kranzler, Joel Gelernter.   

Abstract

Affective disorders (AFDs) are highly comorbid with substance dependence (SD) and both are genetically influenced. However, the specific etiology of the comorbidity is not well understood. We genotyped an array of 1,350 single nucleotide polymorphisms (SNPs) in or near 130 genes in 868 European-Americans (EAs), including 182 individuals with primary AFDs (PAFDs), 214 with SD comorbid with AFD (CAFD), and 472 screened controls. NGFB, which encodes nerve growth factor β and was represented in the array by 15 SNPs, showed the strongest evidence of association, but only among women with PAFDs. Six of the SNPs showed nominally significant association with PAFDs in women (P's = 0.0007-0.01); three (rs2856813, rs4332358, and rs10776799) were empirically significant based on 1,000,000 permutations (P's = 0.008-0.015). Seven haplotypes were significantly associated with PAFDs in women (P's = 0.0014-0.01), of which six were significant based on empirical permutation analysis (minimal P = 0.0045). Four diplotypes were significantly associated with PAFDs in women (global P's = 0.001-0.01). The specific diplotype GG-TC, reconstructed from rs2856813 and rs6678788, showed the strongest evidence of association with PAFDs in women (OR = 4.07, P = 4.2E-05). No SNPs or haplotypes were associated with PAFDs in men or with CAFDs in either sex. We conclude that variation in NGFB is a risk factor for PAFDs in women, but not for CAFD.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21294249      PMCID: PMC3108453          DOI: 10.1002/ajmg.b.31175

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  39 in total

1.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.

Authors:  R L Spitzer; J B Williams; M Gibbon; M B First
Journal:  Arch Gen Psychiatry       Date:  1992-08

2.  Detecting the number of clusters of individuals using the software STRUCTURE: a simulation study.

Authors:  G Evanno; S Regnaut; J Goudet
Journal:  Mol Ecol       Date:  2005-07       Impact factor: 6.185

Review 3.  Comorbidity between substance use disorders and psychiatric conditions.

Authors:  Marc A Schuckit
Journal:  Addiction       Date:  2006-09       Impact factor: 6.526

4.  Influences of neonatal and adult exposures to testosterone on the levels of the beta-subunit of nerve growth factor in the neural tissues of mice.

Authors:  R Katoh-Semba; R Semba; S Kashiwamata; K Kato
Journal:  Brain Res       Date:  1990-07-02       Impact factor: 3.252

Review 5.  Neurobiological similarities in depression and drug dependence: a self-medication hypothesis.

Authors:  A Markou; T R Kosten; G F Koob
Journal:  Neuropsychopharmacology       Date:  1998-03       Impact factor: 7.853

6.  Sex differences in depression and anxiety disorders: potential biological determinants.

Authors:  Margaret Altemus
Journal:  Horm Behav       Date:  2006-08-22       Impact factor: 3.587

7.  Diagnostic reliability of the Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA).

Authors:  Amira Pierucci-Lagha; Joel Gelernter; Richard Feinn; Joseph F Cubells; Deborah Pearson; Alisha Pollastri; Lindsay Farrer; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2005-12-12       Impact factor: 4.492

Review 8.  The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.

Authors:  Guang Chen; Husseini K Manji
Journal:  Curr Opin Psychiatry       Date:  2006-05       Impact factor: 4.741

9.  Changes in depression among abstinent alcoholics.

Authors:  S A Brown; M A Schuckit
Journal:  J Stud Alcohol       Date:  1988-09

10.  Diagnosing comorbidity in substance abusers: a comparison of the test-retest reliability of two interviews.

Authors:  H E Ross; R Swinson; S Doumani; E J Larkin
Journal:  Am J Drug Alcohol Abuse       Date:  1995-05       Impact factor: 3.829

View more
  5 in total

1.  Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review.

Authors:  Yen-Wen Chen; Pao-Yen Lin; Kun-Yu Tu; Yu-Shian Cheng; Ching-Kuan Wu; Ping-Tao Tseng
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-01       Impact factor: 2.570

Review 2.  A Systematic Review of Genetic Polymorphisms Associated with Bipolar Disorder Comorbid to Substance Abuse.

Authors:  Adriano de Marco; Gabriele Scozia; Lucia Manfredi; David Conversi
Journal:  Genes (Basel)       Date:  2022-07-22       Impact factor: 4.141

3.  Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders.

Authors:  Kathryn J Lester; Thalia C Eley
Journal:  Biol Mood Anxiety Disord       Date:  2013-02-07

4.  Neurotrophic gene polymorphisms and response to psychological therapy.

Authors:  K J Lester; J L Hudson; M Tropeano; C Creswell; D A Collier; A Farmer; H J Lyneham; R M Rapee; T C Eley
Journal:  Transl Psychiatry       Date:  2012-05-01       Impact factor: 6.222

5.  Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence.

Authors:  Chetna J Mistry; Monica Bawor; Dipika Desai; David C Marsh; Zainab Samaan
Journal:  Curr Psychiatry Rev       Date:  2014-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.